Fulltext

Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France

Saraux, Alain ; Gossec, Laure ; Goupille, Philippe ; Bregman, Bruno ; Boccard, Eric ; Dupont, Danielle ; Beresniak, Ariel

In: Rheumatology, 2010, vol. 49, no. 4, p. 733-740

Ajouter à la liste personnelle
    Titre
    • Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France
    Auteur
    • Saraux, Alain. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Gossec, Laure. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Goupille, Philippe. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Bregman, Bruno. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Boccard, Eric. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Dupont, Danielle. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    • Beresniak, Ariel. Department of Rheumatology, Brest University, CHU Brest, Brest, Rheumatology B Department, Medicine Faculty, Paris Descartes University, UPRES-EA, APHP, Cochin Hospital, Paris, Rheumatology Department, Tours Hospital, François-Rabelais University, UMR CNRS, Tours, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France, Global Epidemiology and Outcomes Research, Bristol-Myers Squibb International Corporation, Braine L'Alleud, Belgium, LIRAES, Paris-Descartes University, Paris, France and Data Mining International, Geneva, Switzerland.
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:302924
    Summary
    Objectives. Modern treatment of RA includes the use of biologics. Their cost is high and comparison between different treatment strategies is needed. Method. Direct medical costs of RA in France were evaluated based on expert opinion. Then, simulation-decision analytical models were developed to assess four biologic treatment sequences over 2 years in patients failing to respond to at least one anti-TNF agent. Effectiveness was expressed in theoretical expected number of days (TEND) in remission or low disease activity [low disease activity score (LDAS)] based on DAS-28 scores. Results. Direct medical costs of RA in France (excluding the cost of biologics) were estimated at €905 (s.d. 263) for 6 months and €696 (s.d. 240) for each subsequent 6 months (P < 0.001) for patients achieving LDAS and €1215 for 6 months (s.d. 405) for patients not achieving LDAS. Based on LDAS criteria, using abatacept after an inadequate response to the first anti-TNF agent (etanercept) appeared significantly (P < 0.01) more efficacious over a 2-year period (102 TEND) compared with using rituximab at a 6-month re-treatment interval (82 TEND). Mean cost-effectiveness ratios showed significantly lower costs (P < 0.01) per TEND with abatacept as second biologic agent (€278) compared with rituximab (€303). After an inadequate response to two anti-TNF agents, using abatacept also appeared significantly more efficacious than an anti-TNF agent (P < 0.01). All comparisons were confirmed when using remission criteria instead of LDAS. Conclusion. Advanced simulation models based on clinical evidence and medical practice appear to be a promising approach for comparing cost-effectiveness of biologic strategies in RA